TP53 and p21 (CDKN1A) polymorphisms and the risk of systemic lupus erythematosus.
Jacyara Maria Brito MacedoAmanda Lima SilvaAmanda Chaves PintoLeandro Ferreira Lopes LandeiraElyzabeth Avvad PortariCintia Barros Santos-RebouçasEvandro Mendes KlumbPublished in: Advances in rheumatology (London, England) (2023)
Our findings showed that the TP53 and p21 polymorphisms included in this study may have potential to emerge as SLE susceptibility markers for specific groups of patients. Significant interactions of the TP53 polymorphisms with serositis and neurological disorders were also observed in SLE patients.